After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2016.

Diversification didn't pay off very well for Italy's Recordati Industria Chimica & Farmaceutica SPA. The company's revised growth strategy depends mostly on developing assets it already has, principally its fine chemicals business, and an already-approved calcium antagonist called lercanidipine.